Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk factors for stage IV breast cancer at the time of presentation in Turkey.
Uyeturk U, Tatli AM, Gucuk S, Oksuzoglu B, Ulas A, Avci N, Ozbay MF, Gunduz S, Akinci MB, Salim DK, Sonmez OU, Akdag F, Ergenc H. Uyeturk U, et al. Among authors: salim dk. Asian Pac J Cancer Prev. 2013;14(12):7445-9. doi: 10.7314/apjcp.2013.14.12.7445. Asian Pac J Cancer Prev. 2013. PMID: 24460317 Free article.
Leukocytoclastic vasculitis associated with capecitabine.
Arici MO, Avsar E, Kilic O, Salim DK. Arici MO, et al. Among authors: salim dk. J Oncol Pharm Pract. 2024 Oct;30(7):1282-1286. doi: 10.1177/10781552231167812. Epub 2023 Apr 6. J Oncol Pharm Pract. 2024. PMID: 37021460
Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard?
Mutlu H, Salim DK, Gündüz Ş, Eryılmaz MK, Musri FY, Coşkun HŞ. Mutlu H, et al. Among authors: salim dk. J Cancer Res Ther. 2017 Jul-Sep;13(3):510-513. doi: 10.4103/0973-1482.161933. J Cancer Res Ther. 2017. PMID: 28862218 Free article.
The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study.
Özdemir Ö, Zengel B, Yildiz Y, Uluç BO, Cabuk D, Ozden E, Salim DK, Paydas S, Demir A, Diker O, Pilanci KN, Sönmez ÖU, Vatansever S, Dogan I, Gulmez A, Cakar B, Gursoy P, Yildirim ME, Ayhan M, Karadurmus N, Aykan MB, Cevik GT, Sakalar T, Hacibekiroglu I, Gülbagci BB, Dincer M, Garbioglu DB, Kemal Y, Nayir E, Taskaynatan H, Yilmaz M, Avci O, Sari M, Coban E, Atci MM, Esen SA, Telli TA, Karatas F, Inal A, Demir H, Kalkan NO, Yilmaz C, Tasli F, Alacacioglu A. Özdemir Ö, et al. Among authors: salim dk. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310. Epub 2022 Jun 20. Anticancer Drugs. 2022. PMID: 35703239
27 results